Promise of Second Generation Biologics

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
50 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Dec 15, 2011

Dr. Sagar Lonial, a myeloma specialist at Emory's Winship Cancer Institute, is excited about new drugs in trials and research making news at ASH in 2011. He covers the promising medication carfilzomib, slated for FDA review by July 2012; third-generation IMiD, pomalidomide; and combination therapy with the monoclonal antibody, elotuzumab. He also touches on research into the use of HDAC inhibitors to help overcome bortezomib resistance and a possible oral proteasome inhibitor.

  • likes, 0 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more